|Bid||145.69 x 1300|
|Ask||161.75 x 1200|
|Day's Range||150.92 - 154.93|
|52 Week Range||99.15 - 156.21|
|Beta (5Y Monthly)||0.99|
|PE Ratio (TTM)||125.12|
|Earnings Date||Nov 08, 2021 - Nov 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||145.00|
Novanta (NOVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
PVH, WTS, SCSC, and NOVT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 3, 2021
BEDFORD, Mass., September 01, 2021--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chairperson and Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the Baird's 2021 Global Healthcare Conference on Wednesday, September 15, 2021, which is being held virtually.